The re-birth of hepatic arterial infusion for colorectal liver metastases

Journal of Gastrointestinal Oncology

Volumn 4, Issue 2, 2013, Pages 118-120

  Kemeny, Nancy E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; DRUG COST; EDITORIAL; HEPATIC ARTERY; HUMAN; LIVER METASTASIS; LIVER RESECTION; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT;

EID: 84995807119     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2013.019     Document Type: Editorial

References (16)

1. Saridaki Z, Androulakis N, Vardakis N, et al. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. Br J Cancer 2012;107:1932-7.
2. Nanashima A, Takeshita H, Abo T, et al. Recent advances and significance of intra-arterial infusion chemotherapy in nonresectable colorectal liver metastasis. J Gastrointest Oncol 2013. [Epub ahead of print].
3. Durand-Zaleski I, Earlam S, Fordy C, et al. Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases. Cancer 1998;83:882-8.
4. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006;24:1395-403.
5. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984;2:498-504.
6. Ensminger WD, Rosowsky A, Raso V, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res 1978;38:3784-92.
7. van Laar JA, Rustum YM, Ackland SP, et al. Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer 1998;34:296-306.
8. Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002;29:119-25.
9. Boublil JL, Milano G, Khater R, et al. Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation. Br J Cancer 1985;52:15-20.
10. Wagner JG, Gyves JW, Stetson PL, et al. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 1986;46:1499-506.
11. van Riel JM, van Groeningen CJ, Kedde MA, et al. Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 2002;8:405-12.
12. van Riel JM, van Groeningen CJ, de Greve J, et al. Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Ann Oncol 2004;15:59-63.
13. Guthoff I, Lotspeich E, Fester C, et al. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res 2003;23:5203-8.
14. Kemeny N, Kemeny M, Lawrence TS. Liver metastases. In: Abeloff MD, Armitage JO, Lichter AS, et al. eds. Clinical Oncology (3rd Edition). New York: Churchill Livingstone, Inc., 2004:1141-78.
15. Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003;361:368-73.
16. Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009;27:3465-71.